Allarity Therapeutics, Inc. (ALLR)
NASDAQ: ALLR · Real-Time Price · USD
1.190
+0.020 (1.71%)
At close: Jul 17, 2026, 4:00 PM EDT
1.150
-0.040 (-3.36%)
After-hours: Jul 17, 2026, 5:45 PM EDT
Allarity Therapeutics Revenue
Allarity Therapeutics had revenue of $25.00K in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $345.00K. In the year 2025, Allarity Therapeutics had annual revenue of $320.00K.
Revenue (ttm)
$345.00K
Revenue Growth
n/a
P/S Ratio
54.88
Revenue / Employee
$43,125
Employees
8
Market Cap
18.93M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 320.00K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Lipocine | 2.00M |
| SeaStar Medical Holding | 1.44M |
| Longeveron | 1.22M |
| Pluri | 1.08M |
| Neuphoria Therapeutics | -13.27K |
ALLR News
- 11 days ago - Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration - GlobeNewsWire
- 18 days ago - Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic - GlobeNewsWire
- 4 weeks ago - Allarity to present trial-in-progress poster on Phase 2 stenoparib trial - TheFly
- 4 weeks ago - Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026 - GlobeNewsWire
- 2 months ago - Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers - GlobeNewsWire
- 2 months ago - Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm - GlobeNewsWire
- 2 months ago - Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign - GlobeNewsWire
- 2 months ago - Allarity receives notice of allowance from USPTO - TheFly